Serum HE4 profile during primary chemotherapy of epithelial ovarian cancer

International Journal of Gynecological Cancer

Volumn 21, Issue 9, 2011, Pages 1573-1578

  Hynninen, Johanna ^a   Auranen, Annika ^a   Dean, Kirsti ^a   Lavonius, Maija ^a   Carpen, Olli ^a   Perheentupa, Antti ^a,b   Seppänen, Marko ^a   Grénman, Seija ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

CA 125; HE4; Ovarian carcinoma; PET CT; Treatment response

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4; TUMOR MARKER; MEMBRANE PROTEIN; MUC16 PROTEIN, HUMAN; PROTEIN; WFDC2 PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONCENTRATION (PARAMETERS); EARLY DIAGNOSIS; EPITHELIAL OVARIAN CANCER; FEMALE; FOLLOW UP; HUMAN; MULTIMODALITY CANCER THERAPY; OVARY CANCER; PRIORITY JOURNAL; TREATMENT RESPONSE; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BLOOD; METABOLISM; NEOPLASM; OVARIAN EPITHELIAL CANCER; OVARY TUMOR; POSTMENOPAUSE;

ADENOCARCINOMA; CA-125 ANTIGEN; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MEMBRANE PROTEINS; NEOADJUVANT THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POSTMENOPAUSE; PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84857410649     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182225509     Document Type: Article

References (12)

1. Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943-953.
2. Van Der Burg MEL, Lammes FB, Van Putten WLJ, et al. Ovarian cancer: the prognostic value of the serum half-life of CA 125 during induction chemotherapy. Gynecol Oncol. 1988;30:307-312.
3. Riedinger JM, Wafflart J, Ricolleau G, et al. CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. Ann Oncol. 2006;17:1234-1238. (Pubitemid 44288214)
4. Rocconi RP, Matthews KS, Kemper MK, et al. The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer. Gynecol Oncol. 2009;114:242-245.
5. Markman M, Federico M, Liu PY, et al. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer. Gynecol Oncol. 2006;103:195-198. (Pubitemid 44389869)
6. Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108:402-408. (Pubitemid 351174295)
7. Nolen B, Velikokhatnaya L, Marrangoni A, et al. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol. 2010;117:440-445.
8. Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112:40-46.
9. Anastasi E, Marchei GG, Viggiani V, et al. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol. 2010;31:113-119.
10. Avril N, Sassen S, Schmalfeldt B, et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol. 2005;23:7445-7453. (Pubitemid 46291806)
11. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
12. Bast RC Jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883-887. (Pubitemid 13014028)